Dr. Shira Dinner is a hematologist/oncologist at Northwestern University in the Robert H. Lurie Comprehensive Cancer Center. Dr. Dinner specializes in the treatment of acute and chronic leukemias, as well as myelodysplastic syndrome. Her research focuses on early phase clinical trials of molecularly targeted therapies and immunotherapies for leukemias, in particular acute lymphoblastic leukemia. Dr. Dinner received the National Cancer Institute Cancer Clinical Investigator Team Leadership Award to support her research from 2017-2019. She currently serves on several NCCN guideline committees, including for Hematopoietic Growth Factors, MDS, ALL, and Adolescent and Young Adult (AYA) cancers. Dr. Dinner participates in both the Eastern Cooperative Oncology Group and Alliance for Clinical Trials in Oncology Leukemia Committees. She is currently developing two national NCI sponsored trials with the ECOG Leukemia Committee that will open in 2022. Also, given her interest in ALL she has developed expertise in AYA oncology and was appointed the co-chair of the ECOG AYA Committee in 2021. Dr. Dinner serves as the Executive Officer for the Alliance malignant hematology committees. In this role she provides medical and scientific oversight of the Alliance Leukemia, Lymphoma, Multiple Myeloma and Transplant/Cellular Therapy Committees and collaborates closely with the NCI and pharmaceutical companies.